FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SOBECKI CHRISTOPHER J 		2. Issuer Name and Ticker or Trading Symbol

NITROMED INC [ NTMD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O THE INVUS GROUP LLC, 750 LEXINGTON AVENUE 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/24/2009
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   4/24/2009     D    4989024   D   (1) 0   I   See Footnote No. 2   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock (Right to Buy)   $4.12   4/24/2009     D        20000      (3) 5/17/2016   Common Stock   20000     (3) 0   D    
Option to Purchase Common Stock (Right to Buy)   $2.67   4/24/2009     D        15000      (3) 5/25/2017   Common Stock   15000     (3) 0   D    
Option to Purchase Common Stock (Right to Buy)   $1.14   4/24/2009     D        15000      (3) 5/14/2018   Common Stock   15000     (3) 0   D    

Explanation of Responses:
( 1)  Disposed of pursuant to merger agreement between Issuer and entities affiliated with Deerfield Management in exchange for the right to receive $0.8585 per share.
( 2)  Consists of shares held by Invus Public Equities, L.P. Mr. Sobecki, a director of NitroMed, is managing director of The Invus Group, LLC, which is an affiliate of Invus Public Equities, L.P. Mr. Sobecki disclaims beneficial ownership of the shares held by Invus Public Equities, L.P., except to the extent of his pecuniary interest therein.
( 3)  This option was canceled in the merger between the Issuer and entities affiliated with Deerfield Management because its exercise price was greater than the merger consideration of $0.8585 per share.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SOBECKI CHRISTOPHER J
C/O THE INVUS GROUP LLC
750 LEXINGTON AVENUE
NEW YORK, NY 10022 		X



Signatures
/s/ Christopher J. Sobecki 4/28/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nitromed (MM) (NASDAQ:NTMD)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Nitromed (MM) 차트를 더 보려면 여기를 클릭.
Nitromed (MM) (NASDAQ:NTMD)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Nitromed (MM) 차트를 더 보려면 여기를 클릭.